Aviado · Research
Longevity Daily
Tuesday, October 20, 2026
Listen
Today's Brief
Today's standout is a landmark AI study in The Lancet Digital Health: a model trained on 40 million facial photographs estimates biological age with a 5-year margin of error and stratifies mortality risk threefold — making a selfie one of the cheapest longevity biomarkers imaginable. In the lab, cellular recycling research reveals the upstream cause of zombie-cell accumulation, while Life Biosciences publishes the first results from a human epigenetic reprogramming trial. On the clinical side, metformin beats aspirin at cutting a key inflammation marker in a randomized trial of cancer survivors. Aviado's deep dive on Rhodiola's AMPK mechanism rounds out what is a richly data-driven issue.
10 stories2 peer-reviewed3 trials1 Aviado original
Cognitive Health & Neuroprotection
Creatine Isn't Just for Athletes — Older Adults May Need It Most for Brain Health
Most people know creatine as a muscle supplement, but the LA Times highlights growing evidence that it may be even more relevant for cognitive health in older adults — supporting short-term memory, reasoning, and neuroprotection of nerve cells. The safety profile is reassuring: years of studies at 3–5 grams per day have found no meaningful harm in healthy adults. Researchers caution that more large-scale trials are needed before definitive cognitive claims can be made, but for anyone already considering a supplement stack, creatine is hard to argue against.
Read more →Supplements & Compounds
How Rhodiola's Salidroside Activates AMPK to Deliver Measurable Energy and Endurance Gains
Rhodiola rosea works through a precise mechanism: its active compound salidroside activates AMPK — your body's master energy sensor — triggering mitochondrial improvements and a measurable surge in antioxidant enzyme activity. Human studies consistently show increases in VO2max and superoxide dismutase levels, making endurance and oxidative stress protection the most solidly evidenced benefits of this adaptogen. Aviado's analysis concludes that 200–600 mg of a standardized extract (at least 1% salidroside) taken daily for 2–4 weeks is where evidence-backed results reliably emerge.
Read the full Aviado analysis →David Sinclair Breaks Down the Science of Peptides — What Works, What Doesn't
Peptides span a wide spectrum — from collagen supplements at every pharmacy to experimental longevity therapies tested in clinics — and the evidence varies as wildly as the price tags. In Season 2, Episode 11 of Lifespan, David Sinclair and co-host Matthew LaPlante examine the rapidly evolving science, separating legitimate mechanisms from marketing hype. If you've been curious about BPC-157, collagen peptides, or injectable anti-aging protocols, this episode is a useful reference point for what the research actually supports.
Read more →Research & Papers
An AI Trained on 40 Million Faces Can Now Predict Your Biological Age — and Your Survival Odds
Researchers built FAHR-Face, a foundation AI model trained on more than 40 million photographs, that estimates biological age with a mean error of just 5.1 years — outperforming all existing benchmark models — and predicts survival risk from a standard photo of a patient's face. Published in The Lancet Digital Health, the survival prediction model placed the highest-risk quartile at more than three times the mortality rate of the lowest (adjusted hazard ratio 3.23), validated across age, sex, race, and cancer types. The two component models — one for biological age, one for survival — analyze different facial regions and deliver complementary signals, meaning the combined tool outperforms either alone. A low-cost, scalable facial biomarker that works from a standard photograph could transform how clinicians stratify risk, particularly in settings where blood tests and imaging aren't available.
Read more →Life Biosciences Releases First Human Data from the World's First Epigenetic Reprogramming Trial
Life Biosciences has published initial results from the first clinical trial testing partial epigenetic reprogramming — using Yamanaka factors to dial back biological age at the cellular level — bringing a technology that has only existed in animal models into human tissue for the first time. The trial is limited to a specific cell type or tissue region where delivery can be controlled tightly enough to prevent cells from losing their identity (dedifferentiation), a key safety constraint. These early human signals represent among the most closely watched developments in longevity science this year; full peer-reviewed results are expected as the trial progresses.
Read more →Metformin Beats Aspirin at Cutting Inflammation in Cancer Survivors — And the Trial Data Are Clear
In the ASAMET randomized controlled trial — one of the strongest study designs — a full year of metformin significantly reduced NF-κB, the master molecular switch behind chronic inflammation and cancer-survival gene activation, in the colon tissue of 51 colorectal cancer survivors. Aspirin, long studied as a potential cancer-prevention companion, produced no significant effect on the same biomarker. For anyone using or considering anti-inflammatory interventions for long-term health, this is a clean, specific data point: metformin delivers where aspirin doesn't, at least in this tissue and patient population.
Read more →The Body's Cellular Recycling System Is the Real Key to Clearing Zombie Cells — Not Just Killing Them
Scientists have identified chaperone-mediated autophagy — the body's internal cellular housekeeping system — as a critical upstream mechanism for clearing senescent cells before they accumulate and drive the chronic inflammation of aging. Unlike senolytics, drugs that kill zombie cells after they've already built up, this recycling pathway intervenes at the source, offering what researchers describe as a more fundamental and potentially cleaner therapeutic target. Senolytic drugs are already in early trials for frailty and diabetic kidney disease; this finding suggests the field may benefit from also targeting the cause, not just the consequence.
Read more →Lifestyle & Nutrition
Six Clinical Tests That Reliably Predict How Long You'll Live — And You Can Try Them at Home
An elder-care researcher outlines six clinical assessments used by geriatricians to gauge biological age and longevity potential in adults over 60 — including grip strength, walking speed, one-leg balance time, and the ability to rise from a chair without using your hands. These aren't wellness trends; they're validated biomarkers with strong predictive data used routinely in research and clinical settings to assess aging trajectories. If you can pass all six comfortably, the evidence suggests you're aging well; if you can't, each one is also a modifiable, trainable target.
Read more →Industry & Policy
UT Southwestern Is Recruiting Older Adults for a Rapamycin Aging Trial — The RESTOR Study
The RESTOR study at UT Southwestern in San Antonio is actively recruiting older adults to test mTOR inhibition — the pathway targeted by rapamycin — for its effects on age-related functional decline, heart disease risk, and Alzheimer's prevention. This is among the most rigorous human trials to date designed specifically to measure whether a longevity drug can slow aging processes broadly, rather than targeting a single disease. If you're in the San Antonio area, this is a rare opportunity to participate in what could become one of the landmark longevity trials of the decade.
Read more →Loyal's Second FDA-Accepted Canine Longevity Drug Is a Signal for Human Medicine Too
Loyal, the biotech company developing drugs to extend healthy lifespan in dogs, has received a second FDA acceptance for a longevity drug candidate — a regulatory milestone for any company explicitly targeting aging as a therapeutic indication, not just a specific disease. FDA's willingness to engage on aging-as-indication for a second consecutive time signals that a regulatory framework for longevity medicine is quietly taking shape. The longevity field is watching Loyal's dog trials closely: they provide faster, cleaner proof-of-concept than equivalent human studies ever could.
Read more →